metaOBS - - Real World Evidence KB

Treament	Trials	Summary Endpoints
Demonstrated or suggested benefit	Inconclusive results	Uncertain results	Safety results
Immunosuppressants drugs	3	demonstrated 13 % decrease in death D28 demonstrated 13 % decrease in deaths suggested 10 % decrease in death or ventilation	inconclusive results for: death or transfer to ICU; clinical deterioration; clinical improvement; mechanical ventilation; radiologic improvement (14-day); serious adverse events; adverse events	-	-
Immunostimulants drugs	2	none	inconclusive results for: death D28; deaths; viral clearance (time to event analysis only)	suggested 6.5-fold increase in radiologic improvement (14-day) but the degree if certainty is unassessable suggested 90 % decrease in adverse events but the degree if certainty is unassessable	-
leflunomide	1	none	-	-	-
anti-inflammatory therapies	0	-	-	-	-
Apilimod	0	-	-	-	-
corticosteroids	0	-	-	-	-
inhaled corticosteroids	0	-	-	-	-
Kinase inhibitors	0	-	-	-	-
meplazumab	0	-	-	-	-
pirfenidone	0	-	-	-	-
Polyinosinic-Polycytidylic Acid	0	-	-	-	-
sargramostim	0	-	-	-	-
statins	0	-	-	-	-
thymosin	0	-	-	-	-

Treament

Trials

Summary Endpoints

Demonstrated or suggested benefit

Inconclusive results

Uncertain results

Safety results

Immunosuppressants drugs

3

demonstrated 13 % decrease in death D28

demonstrated 13 % decrease in deaths

inconclusive results for: death or transfer to ICU; clinical deterioration; clinical improvement; mechanical ventilation; radiologic improvement (14-day); serious adverse events; adverse events

-

Immunostimulants drugs

2

none

inconclusive results for: death D28; deaths; viral clearance (time to event analysis only)

-

leflunomide

1

none

-

anti-inflammatory therapies

0